DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

GLAXOSMITHKLINE CONS has fifteen approved drugs.

There are ten US patents protecting GLAXOSMITHKLINE CONS drugs.

There are two hundred and eighty-two patent family members on GLAXOSMITHKLINE CONS drugs in forty-three countries and twenty-three supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SPRAY;TOPICAL	021124-002	Mar 17, 2000		OTC	Yes	Yes		Start Trial				Start Trial
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes	7,101,866	Start Trial	Y	Y		Start Trial
Glaxosmithkline Cons	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	021330-001	Oct 31, 2002		OTC	Yes	No		Start Trial				Start Trial
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SOLUTION;TOPICAL	021124-001	Mar 17, 2000		OTC	Yes	Yes		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Cons	EXCEDRIN (MIGRAINE)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998	4,943,565	Start Trial
Glaxosmithkline Cons	LAMISIL	terbinafine hydrochloride	SOLUTION;TOPICAL	020749-001	Oct 17, 1997	4,755,534*PED	Start Trial
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SOLUTION;TOPICAL	021124-001	Mar 17, 2000	5,681,849*PED	Start Trial
Glaxosmithkline Cons	LAMISIL AT	terbinafine	GEL;TOPICAL	021958-001	Jul 24, 2006	5,856,355*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	60 mg	➤ Subscribe	2010-09-08
➤ Subscribe	Gum	4 mg	➤ Subscribe	2013-01-22
➤ Subscribe	Gum	2 mg	➤ Subscribe	2013-01-22

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Denmark	2285411	Start Trial
Spain	2317922	Start Trial
World Intellectual Property Organization (WIPO)	2006109021	Start Trial
World Intellectual Property Organization (WIPO)	2005087615	Start Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1305329	12/2008	Austria	Start Trial	PRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE; REGISTRATION NO/DATE: EU/1/07/434/001 - EU/1/07/434/003 20080111
1305329	326	Finland	Start Trial
2506844	1890025-8	Sweden	Start Trial	PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
1305329	08C0014	France	Start Trial	PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.